Nosocomial infections market impact on diagnostics and therapeutics (mrsa, hap, c. diff and other hospital acquired infections)


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Nosocomial infections market impact on diagnostics and therapeutics (mrsa, hap, c. diff and other hospital acquired infections)

  1. 1. Get more info on this report!Nosocomial Infections: Market Impact on Diagnostics andTherapeutics: (MRSA, HAP, C. diff and other Hospital AcquiredInfections)January 1, 2009A nosocomial, or hospital-acquired, infection is a new infection that is usually defined asan infection that is identified at least forty-eight to seventy-two hours followingadmission, This type of infection is also known as a hospital-acquired infection (or moregenerically healthcare-associated infections).Marketing planners in the pharmaceutical or diagnostic industries should have anunderstanding of the market impact of nosocomial infections, as it will be an importantconsideration in these markets into the near future.This report. Hospital Acquired Infections (Nosocomial) : Diagnostic and PharmaceuticalMarket Considerations : MRSA, HAP, Cdiff and Other market impact of treating thefollowing infections are discussed in detail: Acinetobacter baumannii Clostridium difficile Gastroenteritis Hospital-acquired pneumonia (HAP) and ventilator associated pneumonia Methicillin resistant staphylococcus aureus MRSA Pseudomonas aeruginosa Staphylococcus aureus Stenotrophomonas maltophilia Tuberculosis Urinary tract infection Vancomycin-resistant enterococcusThis report covers nosocomial infection diagnosis and therapeutics in a broad sense. Itdoes not go into the detail of the dynamics of individual products in the marketplace. Itdiscusses, however, the status of the field of nosocomial infection diagnostics andtherapeutics, as a setting-specific field of application.The Most Recent and Relevant Epidemiological Statistics on HAIs
  2. 2. There is no noscomial infection market per se, it is reflected in sales and revenues ofall infectious disease testing and therapeutics. Therefore Kaloramas market analysis inthis report considers primarily the epidemiological considerations and the sizes patientgroups both in the United States and globally, where available. We have accumulatedthe most recent data available, understanding that virtually no organization doesextensive studies on these applications on a regular basis. Many studies are highlylocalized and may only apply to a community, state or country (more often countries thatare not a part of the major markets for nosocomial diagnostic and therapeutic products).In many instances, we have had to draw from broader epidemiologic data, that is, ondata that reach outside of the hospital environment in order to try and construct apicture of the nosocomial testing needs.Estimates of Market ImpactAs mentioned above, the primary focus of this report is on the bacterial form ofnosocomial infections, and those with significant impact on the hospital setting andmarkets. In looking at these infections, we consider the diagnostic and therapeuticstechnologies that are currently available and attempt to project trends in these productareas. Company Profiles and Competitive AssessmentThis report examines the key players in HAI infection diagnostics and pharmaceuticaltreatement, their revenues, and activity in the market. To some extent, we are limited bythe activity of the industries associated with the diagnosis and treatment of theseinfections. For the most part, these activities are limited and the advanced technologiesseen in other areas of medical application are not necessarily present in terms ofmicrobiology. This presages opportunities for new competitorsThe analysis presented in this report is based on data from a combination of company,government, industry, institutional and private sources. It includes information fromextensive literature reviews and discussions with experts in the field, includingmicrobiologists, pathologists, hospital authorities, research scientists, businessdevelopment managers and marketing managers.TABLE OF CONTENTSCHAPTER ONE: EXECUTIVE SUMMARY Specific Nosocomial Infections Acinetobacter Baumannii Clostridium Difficile Gastroenteritis Hospital-Acquired Pneumonia (HAP) Ventilator-Associated Pneumonia (VAP) Pseudomonas Aeruginos Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
  3. 3. Stenotrophomonas Maltophilia Tuberculosis Urinary Tract Infections Vancomycin-Resistant Enterococcus Scope and Methodolog Market Considerations Trends Affecting Nosocomial Infection ApplicationsCHAPTER TWO: OVERVIEW OF NOSOCOMIAL INFECTIONS Overview Specific Nosocomial Infections o Acinetobacter Baumannii o Clostridium Difficile o Gastroenteritis o Hospital-Acquired Pneumonia  Healthcare-Associated Pneumonia  Hospital-Acquired Pneumonia  Ventilator-Associated Pneumonia o Pseudomonas Aeruginosa o Staphylococcus Aureus o Stenotrophomonas maltophilia o Tuberculosis o Urinary Tract InfectionsCHAPTER THREE: DRUG-RESISTANT NOSOCOMIAL INFECTIONS Overview Drug-Resistant Acinetobacter Drug-Resistant C. Difficile Drug-Resistant Enterococci Drug-Resistant Pneumonia Drug-Resistant Pseudomonas Aeruginosa Drug-Resistant Staphylococcus Aureus Drug-Resistant Tuberculosis Drug-Resistance/Susceptibility Testing Genotypic Methods o DNA Sequencing o Solid-phase Hybridization Techniques o Microarrays o Real-time Polymerase Chain Reaction Techniques o Phenotypic Method o Phage-based Assay o Colorimetric Method o The Nitrate Reductase Assay
  4. 4. CHAPTER FOUR: EPIDEMIOLOGICAL MARKET CONSIDERATIONS Overview o Acinetobacter Baumannii o Clostridium Difficile o Enterococci o Drug-Resistant Pneumonia o Pseudomonas aeruginosa o Staphylococcus aureus o Drug Resistant TuberculosisCHAPTER FIVE: COMPANY SNAPSHOTS Abbott Pharmaceuticals (Division of Abbott Laboratories) AdvanDx, Inc. Becton Dickinson and Company Binax, Inc. (Division of Inverness Medical Innovations) Cellestis Cepheid GeneOhm Sciences (Division of Becton Dickinson) GlaxoSmithKline plc Meridian Bioscience, Inc. Merck & Co. Schering-Plough Techlab, Inc. Trek Diagnostics Systems, Ltd. (A Subsidiary of Magellan Biosciences) Volu SolCHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS First Conclusion o Implications Second Conclusion o Implications Third Conclusion o Implications Fourth Conclusion o Implications Fifth Conclusion o Implications Sixth Conclusion o Implications Seventh Conclusion o ImplicationsAvailable immediately for Online Download at
  5. 5. 800.298.5699UK + +1.240.747.3093Fax: 240.747.3004